[go: up one dir, main page]

CN1260703A - 治疗由病毒和微生物感染和消瘦综合症的给药装置及方法 - Google Patents

治疗由病毒和微生物感染和消瘦综合症的给药装置及方法 Download PDF

Info

Publication number
CN1260703A
CN1260703A CN98806085A CN98806085A CN1260703A CN 1260703 A CN1260703 A CN 1260703A CN 98806085 A CN98806085 A CN 98806085A CN 98806085 A CN98806085 A CN 98806085A CN 1260703 A CN1260703 A CN 1260703A
Authority
CN
China
Prior art keywords
dmf
acetamide
therapeutic combination
treatment
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98806085A
Other languages
English (en)
Chinese (zh)
Inventor
米歇尔·奥尔加·帕特里夏·吉斯泰瑞·维瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cryopreservation Technologies CC
Original Assignee
Cryopreservation Technologies CC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/874,425 external-priority patent/US5935597A/en
Application filed by Cryopreservation Technologies CC filed Critical Cryopreservation Technologies CC
Publication of CN1260703A publication Critical patent/CN1260703A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN98806085A 1997-06-13 1998-06-09 治疗由病毒和微生物感染和消瘦综合症的给药装置及方法 Pending CN1260703A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/874,425 1997-06-13
US08/874,425 US5935597A (en) 1995-12-15 1997-06-13 Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes

Publications (1)

Publication Number Publication Date
CN1260703A true CN1260703A (zh) 2000-07-19

Family

ID=25363728

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98806085A Pending CN1260703A (zh) 1997-06-13 1998-06-09 治疗由病毒和微生物感染和消瘦综合症的给药装置及方法

Country Status (34)

Country Link
EP (1) EP1011567A1 (is)
JP (1) JP4531141B2 (is)
KR (1) KR20010013709A (is)
CN (1) CN1260703A (is)
AP (1) AP1629A (is)
AR (1) AR012970A1 (is)
AU (1) AU7831598A (is)
BG (1) BG103997A (is)
BR (1) BR9810095A (is)
CA (1) CA2295176A1 (is)
CZ (1) CZ298510B6 (is)
EA (1) EA200000011A1 (is)
EE (1) EE9900562A (is)
ES (1) ES2161187B1 (is)
FI (1) FI19992648L (is)
GB (1) GB2341319B (is)
HU (1) HUP0003034A2 (is)
ID (1) ID23516A (is)
IL (2) IL133396A0 (is)
IS (1) IS5289A (is)
LT (1) LT4714B (is)
LV (1) LV12490B (is)
NO (1) NO996117L (is)
NZ (1) NZ501669A (is)
OA (1) OA11307A (is)
PL (1) PL196256B1 (is)
RO (1) RO121252B1 (is)
SI (1) SI20191A (is)
SK (1) SK172299A3 (is)
TN (1) TNSN98086A1 (is)
TR (1) TR200000540T2 (is)
WO (1) WO1998056325A1 (is)
YU (1) YU66099A (is)
ZA (1) ZA984649B (is)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100586385C (zh) * 2003-06-30 2010-02-03 阿尔扎公司 经皮递送装置及其形成方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2006003648A0 (en) * 2003-12-05 2006-06-30 Namibia Medical Invest Pty Ltd Patch

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
US5534260A (en) * 1989-02-23 1996-07-09 University Of Utah Percutaneous drug delivery system
US5028435A (en) * 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US5624912A (en) * 1991-08-21 1997-04-29 Burcoglu; Arsinur Method of treating HIV infection and related secondary infections with defibrotide
NZ249032A (en) * 1992-02-20 1996-09-25 Merrell Dow Pharma Stilbene disulphonic acid derivatives substituted in the 4- and 4'-positions by thioureido, thiocarbonate ester, and thiocarbamate and thiocarbamoyloxy (and -omino) and thioamide groups; use in treating viral diseases
IL124733A0 (en) * 1995-12-15 1999-01-26 Cryopreservation Tech Cc Composition for organ cryopreservation and treatment of viral and bacterial infections

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100586385C (zh) * 2003-06-30 2010-02-03 阿尔扎公司 经皮递送装置及其形成方法

Also Published As

Publication number Publication date
TR200000540T2 (tr) 2000-09-21
EA200000011A1 (ru) 2000-08-28
AR012970A1 (es) 2000-11-22
NO996117D0 (no) 1999-12-10
IL133396A0 (en) 2001-04-30
ID23516A (id) 2000-04-27
BR9810095A (pt) 2001-11-13
IL133396A (en) 2006-10-05
SI20191A (sl) 2000-10-31
AU7831598A (en) 1998-12-30
KR20010013709A (ko) 2001-02-26
LT99148A (lt) 2000-07-25
PL196256B1 (pl) 2007-12-31
EP1011567A4 (en) 2000-06-28
JP2002511862A (ja) 2002-04-16
CZ9904473A3 (cs) 2001-03-14
LV12490B (en) 2000-12-20
IS5289A (is) 1999-12-08
ZA984649B (en) 1999-12-17
WO1998056325A1 (en) 1998-12-17
FI19992648A7 (fi) 2000-02-03
YU66099A (sh) 2002-10-18
AP9901708A0 (en) 1999-12-31
LT4714B (lt) 2000-10-25
EP1011567A1 (en) 2000-06-28
EE9900562A (et) 2000-06-15
ES2161187B1 (es) 2003-08-16
CA2295176A1 (en) 1998-12-17
BG103997A (bg) 2001-07-31
NZ501669A (en) 2001-09-28
GB2341319B (en) 2002-02-27
TNSN98086A1 (fr) 2005-03-15
GB2341319A (en) 2000-03-15
OA11307A (en) 2003-10-24
RO121252B1 (ro) 2007-02-28
JP4531141B2 (ja) 2010-08-25
PL338439A1 (en) 2000-11-06
GB9929189D0 (en) 2000-02-02
HUP0003034A2 (hu) 2000-12-28
NO996117L (no) 2000-02-11
SK172299A3 (en) 2000-09-12
ES2161187A1 (es) 2001-11-16
FI19992648L (fi) 2000-02-03
AP1629A (en) 2006-07-11
LV12490A (en) 2000-06-20
CZ298510B6 (cs) 2007-10-24

Similar Documents

Publication Publication Date Title
DK173752B1 (da) Anvendelse af dihydroliponsyre til fremstilling af et lægemiddel til bekæmpelse af sygdomme fremkaldt af retrovirus.
Pawlotsky et al. Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase
IE64518B1 (en) Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxyinosine 2',3'-dideoxyguanosine or 2',3'-dideoxyadenosine
Broder et al. Antiretroviral therapy in AIDS
WO1988006396A2 (en) Method for the treatment of aids virus and other retroviruses
Nelson et al. Emtricitabine (FTC) for the treatment of HIV infection
US5935597A (en) Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes
Levi et al. Combination chemotherapy of adult acute nonlymphoblastic leukemia
Nitti et al. Pharmacokinetic study of intravenous rifampicin
CN1260703A (zh) 治疗由病毒和微生物感染和消瘦综合症的给药装置及方法
US5254587A (en) Methods for treating AIDS
Islam et al. An in‐depth analysis of COVID‐19 treatment: Present situation and prospects
VONSOVER et al. Inhibition of the reverse transcriptase activity and replication of human immunodeficiency virus type 1 by AS 101 in vitro
US5089508A (en) Methods for treating aids
Zeidner et al. Treatment of FeLV-induced immunodeficiency syndrome (FeLV-FAIDS) with controlled release capsular implantation of 2′, 3′-dideoxycytidine
Chokekijchai et al. In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI
Chattopadhyay et al. Adefovir-induced Stevens-Johnson syndrome and toxic epidermal necrolysis overlap syndrome
CA2374198A1 (en) Combination therapy for treatment of fiv infection
Kalnina et al. Evaluation of anti-HIV-1 (Retroviridae: Orthoretrovirinae: Lentivirus: Human immunodeficiency virus type 1) activity of 6HP and 3TC in vitro using MT-4 cell line variants with different replicative activity
Pagare et al. REMDESIVIR AFFECT ON COVID-19
CA2509731A1 (en) Treatment of hiv infection through combined administration of tipranavir and capravirine
Colorado Therapy of Presymptomatic FeLV-Induced Immunodeficiency Syndrome with AZT in Combination with Alpha Interferon~
Yeni et al. Antiretroviral and immune-based therapies: update
Zhang et al. Pharmacokinetics of lamivudine in cats
Wang Evaluation of 5-halo-6-alkoxy (or azido)-5, 6-dihydro analogs as prodrugs of nucleoside reverse transcriptase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: CRYOPRESERVATION TECHNOLOGIES C C TO: WHARTON DRUGS HOLDINGS CO., LTD.

CP03 Change of name, title or address

Address after: Ritter Fontaine

Applicant after: Walton pharmaceuticals Holdings Ltd

Address before: Pretoria

Applicant before: Cryopreservation Technologies C C

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication